Biocardia Inc BCDA

$0.83 +0.01 (0.61%)

Valuation

Market cap
12,505,000
Revenue TTM
$0
Net income TTM
$-8,230,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
79,900
Avg volume
218,902
Day's range
$0.82 – $0.97
Shares out
15,139,000
Stochastic %K
53%
Beta
0.69
Analysts
Moderate Buy
Price target
$15.50

Price

Company profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic...

Show more

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 226 0120
Website
https://www.biocardia.com
Address
320 Soquel Way, Sunnyvale, United States

Latest news

Stocktwits

Jusme Nov 13, 11:45 PM
$BCDA Shorts 🪰💩working hard to manipulate the stock price on low volume….
1 replies
Wizee13 Nov 13, 7:03 PM
$BCDA They didn't even mention possible dilution at the earnings or am I wrong? So they know they are very close to make some deal to earn some cash this Q
1 replies
Merlintrader Nov 13, 4:42 PM
$BCDA BioCardia, Nov 12: Q3 net loss of 1.9 million dollars and cash of 2.2 million at Sept 30, with runway the company expects into 2027. Not investment advice. Read more in the $BCDA stock hub: https://www.merlintrader.com/biocardia-bcda-stock-hub/
0 replies
ReversalRuler Nov 13, 3:18 PM
Thanks for the tips bro I made 14k! Follow this guy @SqueezeSpecs he's on fire🔥 $BCDA $BBCI $CDNL 🖤
0 replies
Jusme Nov 13, 12:40 PM
$BCDA BioCardia stock is short sale restricted today following a 400K short position opened yesterday… of which 300k is still short. I noticed that my numerous buy orders yesterday were in constant competition with an algo trading agent which was trying capture the least cost seller’s bid to cover, but remain $.0001 above my bids. Key point: Yesterday’s huge drop was the result of multiple large short orders - *not* stockholders selling - unless they had open stop-loss orders that triggered when the large short sales were placed. Today you may be able to buy shares in the $.80’s…. but if the shorts cover their open position, it will quickly retrace into the $.90’s+.
1 replies
Jusme Nov 13, 3:35 AM
$BCDA Pay attention to the available shares to short…. the outcome of today’s trading session was prefictable. Notice what happened at todays’s openwindow to borrow shares? 400k shares borrowed… see the pattern. Next watch for the reverse before the next FINRA short reporting date…. they seek to cover their tracks. My bet? Intracoastal Capital.
0 replies
chris_stocks Nov 12, 10:46 PM
$BCDA this is like the only stock that can have its earnings up 50% and it's sp still only rises a few pennies. Lol 😂😂😂
1 replies
NineLinesCat Nov 12, 10:29 PM
$BCDA ...feeling pretty good about the coming months. any thoughts...
1 replies